Clinical trials: Treatment-as-usual
Schizophrenia
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered…
- Trial name
- PROSIPAL (NCT01081769)
- Testing
- paliperidone palmitate injection, oral antipsychotics
- Where
- 94 sites in Austria, Belgium and 23 more
- Volunteers
- 769 people
- Sponsor
- Janssen-Cilag International NV
Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission
Anxiety in Recovering Opiate Dependence
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence.
- Conditions
- Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
- Trial name
- NCT00668265
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Medical Center
Bipolar Disorder
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in adult patients.
- Trial name
- NCT01467713
- Testing
- Ramelteon SL
- Where
- 156 sites in United States, Argentina and 3 more
- Volunteers
- 642 people
- Sponsor
- Takeda
Schizophrenia
L-arginine in Treatment as Usual in Schizophrenia
STUDY OBJECTIVES: To determine whether the addition of L-arginine to treatment as usual (TAU) in schizophrenia further improves and enhances therapeutic efficacy (positive, negative and depressive symptoms) and effectiveness of…
- Trial name
- NCT00718510
- Testing
- L-Arginine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Alberta
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Suicide, Suicidal Ideation
Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations
The purpose of the proposed study is to identify the most effective brief interventions for reducing short-term risk for suicide attempts in "real world" military triage settings, and to identify potential mechanisms of change…
- Trial name
- BISSR (NCT02042131)
- Testing
- Treatment As Usual (TAU), Standard Crisis Response Plan (S-CRP), Enhanced Crisis Response Plan (E-CRP)
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Utah
Suicide, Suicidal Ideation
Brief Cognitive Behavioral Therapy for Military Populations
The primary purpose of this study is to compare the effectiveness of brief cognitive-behavioral therapy (B-CBT) for the treatment of suicidality, including suicidal ideation and attempts (regardless of Axis I or II diagnosis)…
- Trial name
- NCT02038075
- Testing
- Brief Cognitive Behavioral Therapy (BCBT), Treatment As Usual (TAU)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Utah
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Postpartum Depression
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.
- Trial name
- NCT05551195
- Testing
- WB001, ED001
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Woebot Health
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Major Depressive Disorder
Automatic Self Transcending Meditation Versus Treatment as Usual
Depression is a leading contributor to global burden of disease. Antidepressants do not provide adequate response for many patients.
- Trial name
- NCT02149810
- Testing
- Automatic Self Transcending Meditation
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Depression, Bipolar Disorder
Liothyronine (T3) for Bipolar Depression
This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.
- Trial name
- T3 (NCT00790738)
- Testing
- Liothyronine (T3)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health
Modified DECIDE Intervention, Treatment as Usual Care Group
The DECIDE Parent-Provider Intervention
The DECIDE Parent-Provider Intervention is designed to support parents caring for adolescents who are receiving treatment for Disruptive, Impulse-Control, and Conduct disorders.
- Trial name
- NCT04445155
- Testing
- Modified DECIDE Parent and Provider Intervention
- Where
- 5 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Stress Disorders, Post-Traumatic
Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU
This study is designed to examine three treatment conditions for traumatized youth: Cue-Centered Treatment (CCT), Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT), and Treatment as Usual (TAU) to determine which treatment…
- Trial name
- NCT02926677
- Testing
- Cue-Centered Treatment (CCT), Trauma-Focused CBT (TF-CBT), Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Stanford University
Osteoarthritis, Knee, Osteoarthritis, Hip
Increasing Physical Activity in Older Adults With Osteoarthritis Pain: Examining a Brief Behavioral Intervention
The purpose of this study is to evaluate how older adults might benefit from sessions that teach behavioral coping skills for increasing physical activity and reducing interference from arthritis pain.
- Trial name
- NCT04490395
- Testing
- Engage PA, Treatment as Usual plus (TAU+)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00776984
- Testing
- tiotropium 5mcg/day
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 453 people
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Dual Diagnosis
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for…
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00498550
- Testing
- Clozapine, Treatment as usual
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC